Takeda Pharmaceutical
- Market cap
- 58.68B
- P/E (TTM)i
- -55.67
- P/Bi
- 1.23
- EPSi
- -0.31
- Div yieldi
- 3.26%
- 52W posi
- 88%
Anonymous reader poll. Unscientific, not investment advice.
Takeda Pharmaceutical shares were changing hands at 18.37, up 1.49% on the day. The company carries a market value of roughly 58.68B, the #400 most valuable US-listed company we track. Valuation-wise, the P/E sits at -53.81, 241% below the five-year average of 38.29. It pays a dividend yielding 3.26% on a trailing basis. Across 1 analysts the consensus rating is Buy, with an average price target of 42.99 (+134%). Over the past year the stock has ranged from 12.77 to 19.10; it now sits 88% up that band.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 months.
- Recent price momentum is +18.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 42.5x | Better than 11% |
| Price / Sales | 1.9x | Better than 65% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.8% | Better than 37% |
| Net income CAGR (3Y) | -22.3% | Better than 15% |
| Free cash flow CAGR (3Y) | 22.2% | Better than 66% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 65.1% | Better than 79% |
| Operating margin | 10.3% | Better than 36% |
| Net margin | -3.4% | Better than 10% |
| Return on equity | -2.1% | Better than 13% |
| Return on invested capital | -0.6% | Better than 14% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 5.0% | Better than 66% |
| 6-month return | -2.6% | Better than 34% |
| 12-month return (ex latest month) | 29.0% | Better than 65% |
| Distance below 52-week high | 6.8% | Better than 86% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.1x | Better than 30% |
| Debt to assets | 65.7% | Better than 18% |
| Interest coverage | 0.0x | Better than 12% |
| Free cash flow / net income | 627.8% | Better than 96% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 18.10
- Open
- 18.14
- Day range
- 18.14 - 18.46
- Avg price
- 18.36
- Volume
- 2.56M
- Turnover
- 46.93M
- Turnover ratei
- 0.08%
- Volume ratioi
- 0.94
- Amplitudei
- 1.74%
- 52-week rangei
- 12.77 - 19.10
Valuation
- P/Ei
- -60.03
- P/E (TTM)i
- -55.67
- P/Bi
- 1.23
- EPSi
- -0.31
- Book value / shi
- 14.97
- Net profit
- -977.54M
- Net assets
- 47.81B
Share structure
- Market cap
- 58.68B
- Float capi
- 56.82B
- Shares out
- 3.19B
- Float sharesi
- 3.09B
Dividend & listing
- Div yield (TTM)i
- 3.26%
- Dividend (TTM)
- 0.60
- Listing date
- 1970-01-01
3.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.40M net over the window
Short interest
- Shares short
- 4.20M
- % of floati
- 0.13%
- Days to coveri
- 1.95
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Takeda Pharmaceutical (TAK)?
Takeda Pharmaceutical last traded at 18.37. The quote on this page refreshes every few seconds while US markets are open.
What is Takeda Pharmaceutical's market cap?
About 58.68B.
What is the P/E ratio of Takeda Pharmaceutical?
The trailing twelve-month P/E is -55.67, below its own 5-year average of 38.29 — toward the bottom of its historical range (3.99% percentile). See the Valuation tab for the full history.
Does Takeda Pharmaceutical pay a dividend?
Yes. The trailing dividend yield is 3.26%. The 2025 payout was up 6.9% from 2024. See the Dividends tab for the full payment history.
Is Takeda Pharmaceutical a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 42.99, which implies 134.0% upside from the current price. This is not investment advice.
What is Takeda Pharmaceutical's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Takeda Pharmaceutical a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 07:37:49 · For reference only, not investment advice and not tailored to your situation.